Skip to main content

Table 3 Exhaled Nitric Oxide

From: The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma

  Day 1
Pre-dose
Day 7
Pre-dose
Day 7
1 hr post-dose
GSK256066 (ppb) 39.9
(31.0 to 51.3)
34.7
(26.7 to 45.0)
36.1
(28.1 to 46.3)
Placebo (ppb) 34.5
(24.6 to 48.4)
33.1
(22.8 to 47.9)
34.3
(23.2 to 50.6)
Adjusted treatment ratio GSK256066 vs placebo   0.98
(0.85 to 1.31)
1.03
(0.88 to 1.20)
  1. Mean values shown, and with adjusted mean (95% confidence intervals) for treatment differences and ratios